Cyprotex plc Surges to 52-Week High, Is Now Top Performer

 Cyprotex plc Surges to 52 Week High, Is Now Top Performer

The stock of Cyprotex plc (LON:CRX) hit a new 52-week high and has GBX 298.26 target or 89.00% above today’s GBX 157.81 share price. The 6 months bullish chart indicates low risk for the GBX 35.59 million company. The 1-year high was reported on Nov, 8 by Barchart.com. If the GBX 298.26 price target is reached, the company will be worth GBX 31.68M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.84% or GBX 1.31 on November 8, hitting GBX 157.81. About 27,044 shares traded hands or 43.97% up from the average. Cyprotex plc (LON:CRX) has risen 60.51% since April 8, 2016 and is uptrending. It has outperformed by 58.56% the S&P500.

More recent Cyprotex plc (LON:CRX) news were published by: Businesswire.com which released: “Evotec AG Announces Its Intent to Acquire Cyprotex PLC” on October 26, 2016. Also Uk.Finance.Yahoo.com published the news titled: “-LSE Ticker: P25RZ1/ISIN: GB00BP25RZ14” on August 15, 2013. Bizjournals.com‘s news article titled: “Cytocentrics CEO: San Antonio to get big boost from new deal” with publication date: February 10, 2016 was also an interesting one.

Cyprotex PLC is a holding company. The Firm and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. The company has a market cap of 35.59 million GBP. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. It currently has negative earnings. The Company’s in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment